Profile data is unavailable for this security.
About the company
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
- Revenue in JPY (TTM)21.17bn
- Net income in JPY6.23bn
- Incorporated1973
- Employees994.00
- LocationShin Nippon Biomedical Laboratories Ltd28F, St Luke's Tower, 8-1, Akashi-choCHUO-KU 104-0044JapanJPN
- Phone+81 355655001
- Fax+81 355656160
- Websitehttps://www.snbl.co.jp/
More ▼
Mergers & acquisitions
| Acquired company | 2395:TYO since announced | Transaction value |
|---|---|---|
| Ina Research Inc | 51.12% | 20.97m |
Data delayed at least 20 minutes, as of Feb 03 2023 06:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| StemRIM Inc | 0.00 | -1.97bn | 54.57bn | 44.00 | -- | 5.98 | -- | -- | -33.22 | -33.22 | 0.00 | 152.20 | 0.00 | -- | -- | 0.00 | -19.82 | -10.05 | -20.00 | -10.24 | -- | -- | -- | -84.44 | 86.65 | -16,696.51 | 0.0003 | -- | -98.36 | -40.18 | -234.50 | -- | -- | -- |
| GNI Group Ltd | 15.91bn | 847.96m | 58.27bn | 629.00 | 69.48 | 2.54 | 44,075.33 | 3.66 | 17.66 | 17.66 | 333.11 | 482.41 | 0.4805 | 1.55 | 6.69 | 25,301,370.00 | -1.50 | 2.39 | -1.63 | 3.17 | 85.56 | 85.26 | -3.11 | 6.04 | 6.15 | 2.92 | 0.3398 | 0.00 | 29.84 | 57.56 | -15.26 | -- | 140.50 | -- |
| Katakura Industries Co., Ltd. | 33.88bn | 1.79bn | 60.78bn | 1.06k | 31.97 | 0.8307 | 13.19 | 1.79 | 53.99 | 53.99 | 1,020.07 | 2,077.86 | 0.2494 | 2.72 | 5.33 | 31,989,610.00 | 1.09 | 1.93 | 1.48 | 2.84 | 36.15 | 36.74 | 4.36 | 6.37 | 2.69 | -- | 0.1475 | 21.11 | -5.08 | -4.32 | 72.52 | 23.98 | -16.80 | 9.86 |
| Eiken Chemical Co Ltd | 45.03bn | 6.54bn | 69.01bn | 745.00 | 9.03 | 1.19 | 9.79 | 1.53 | 175.57 | 175.57 | 1,208.08 | 1,329.46 | 0.7061 | 2.79 | 3.38 | 60,436,240.00 | 10.26 | 8.28 | 12.80 | 10.85 | 48.98 | 45.35 | 14.54 | 11.04 | 2.43 | -- | 0.0575 | 31.27 | 11.20 | 5.26 | 23.28 | 16.34 | 20.51 | 15.33 |
| TORII PHARMACEUTICAL CO., LTD. | 48.87bn | 3.99bn | 89.28bn | 560.00 | 21.82 | 0.7365 | 20.10 | 1.83 | 142.09 | 142.09 | 1,739.26 | 4,209.04 | 0.3782 | 2.73 | 2.41 | 87,258,930.00 | 3.09 | 6.82 | 3.37 | 7.85 | 49.14 | 51.06 | 8.17 | 15.53 | 8.03 | -- | 0.00 | 16.78 | 12.68 | -4.84 | -3.46 | 3.51 | -13.22 | 0.00 |
| TOWA PHARMACEUTICAL CO., LTD | 173.86bn | 9.36bn | 102.98bn | 4.08k | 10.71 | 0.7092 | 4.40 | 0.5923 | 186.62 | 186.62 | 3,473.48 | 2,818.59 | 0.5752 | 1.45 | 3.68 | 42,633,890.00 | 3.10 | 5.90 | 4.33 | 7.84 | 39.10 | 44.12 | 5.39 | 10.22 | 0.8056 | -- | 0.518 | 16.48 | 6.92 | 14.28 | 14.01 | 23.34 | -8.50 | 12.47 |
| Shin Nippon Biomedical Laboratories Ltd | 21.17bn | 6.23bn | 104.00bn | 994.00 | 16.69 | 3.69 | 13.45 | 4.91 | 149.68 | 149.68 | 508.61 | 676.88 | 0.4409 | 1.60 | 5.98 | 21,301,740.00 | 13.05 | 5.06 | 18.91 | 7.65 | 53.43 | 45.48 | 29.60 | 14.97 | 0.8221 | -- | 0.373 | 24.13 | 17.46 | 0.5778 | 94.65 | -- | 9.71 | -- |
| KYORIN Holdings, Inc. | 105.53bn | 5.05bn | 107.18bn | 2.22k | 18.81 | 0.7622 | 12.12 | 1.02 | 88.18 | 88.18 | 1,841.56 | 2,176.73 | 0.621 | 1.30 | 3.04 | 47,491,000.00 | 2.97 | 3.33 | 3.66 | 4.03 | 46.13 | 51.06 | 4.79 | 5.46 | 1.87 | -- | 0.1443 | 70.59 | 2.56 | -1.77 | -35.86 | -11.65 | 0.338 | -2.16 |
| Zeria Pharmaceutical Co Ltd | 66.16bn | 5.90bn | 110.59bn | 1.74k | 15.60 | 1.40 | 13.60 | 1.67 | 133.42 | 133.42 | 1,492.07 | 1,489.11 | 0.5030 | 1.53 | 3.55 | 38,087,390.00 | 4.50 | 3.10 | 7.05 | 4.98 | 71.91 | 71.28 | 8.95 | 5.92 | 0.7919 | 4.67 | 0.4396 | 45.87 | 12.84 | -1.70 | 26.03 | 2.25 | -17.52 | 1.81 |
| Kissei Pharmaceutical Co Ltd | 66.93bn | 12.77bn | 127.46bn | 1.83k | 8.88 | 0.5793 | 10.21 | 1.90 | 276.89 | 276.89 | 1,451.39 | 4,246.43 | 0.2848 | 1.68 | 2.50 | 36,614,330.00 | 5.48 | 3.16 | 5.98 | 3.42 | 48.58 | 55.98 | 19.23 | 10.45 | 4.18 | -- | 0.0078 | 34.12 | -5.31 | -1.83 | 144.48 | 10.83 | -5.39 | 4.01 |
| Mochida Pharmaceutical Co Ltd | 109.37bn | 9.58bn | 135.74bn | 1.54k | 13.37 | 0.9755 | 11.10 | 1.24 | 252.77 | 252.77 | 2,899.75 | 3,464.88 | 0.678 | 2.24 | 3.58 | 70,835,500.00 | 5.94 | 5.22 | 7.12 | 6.40 | 53.99 | 51.57 | 8.75 | 7.76 | 3.62 | -- | 0.00 | 40.56 | 6.98 | 2.51 | 23.08 | 4.39 | 21.99 | 3.04 |
Data as of Feb 03 2023. Currency figures normalised to Shin Nippon Biomedical Laboratories Ltd's reporting currency: Japanese Yen JPY
13.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Asset Management One Co., Ltd.as of 13 Jan 2023 | 2.13m | 5.12% |
| Nomura Asset Management Co., Ltd.as of 30 Dec 2022 | 643.60k | 1.55% |
| The Vanguard Group, Inc.as of 05 Jan 2023 | 502.94k | 1.21% |
| Sumitomo Mitsui DS Asset Management Co., Ltd.as of 30 Dec 2022 | 451.90k | 1.09% |
| Daiwa Asset Management Co. Ltd.as of 30 Dec 2022 | 384.30k | 0.92% |
| Dimensional Fund Advisors LPas of 05 Jan 2023 | 354.40k | 0.85% |
| Nikko Asset Management Co., Ltd.as of 06 Jan 2023 | 314.90k | 0.76% |
| Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Oct 2022 | 294.90k | 0.71% |
| Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 05 Jan 2023 | 257.70k | 0.62% |
| BlackRock Fund Advisorsas of 04 Jan 2023 | 226.50k | 0.54% |
More ▼
Data from 30 Sep 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
